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Background:  Little  is known  on the performance  of  the  newly  introduced  health  beneﬁt
assessment  process,  AMNOG,  in  Germany  compared  to other  health  technology  assessment
agencies.
Objective:  We  analysed  whether  decisions  of  the  German  Federal  Joint  Committee  (FJC)
deviate from  decisions  of  the UK  National  Institute  for Health  and  Care Excellence  (NICE),  the
Scottish  Medicines  Consortium  (SMC)  and  the  Australian  Pharmaceutical  Beneﬁts  Advisory
Committee  (PBAC).
Methods: We  analysed  decisions  made  for comparable  patient  subgroups  by the  four  agen-
cies between  2011 and  2014.  First,  decisions  were compared  (a)  by  their  ﬁnal  outcome,  i.e.
whether  a health  beneﬁt  was identiﬁed,  and (b) by  the  agencies’  judgement  on  compar-
ative  effectiveness.  Subsequently,  we partially  explored  reasons  for  differences  between
HTA agencies.
Results:  From  the  192  FJC  decisions,  we  identiﬁed  55 that  overlapped  with  NICE,  166
with  SMC  and 119  with  PBAC.  FJC  agreed  with  NICE  in  40%  in ﬁnal  outcome  (Cohen’s
Kappa  = −0.13).  Similar  results  were  obtained  for  FJC  and SMC  (47.6%,  kappa  = 0.03)  and FJC
and  PBAC  (48.7%,  kappa  =  0.07).  Agreement  increased  when  comparing  judgements  based
on comparative  effectiveness  only.  However,  the  FJC’s  ﬁnal  decision  was  positive  only  in
43.6%, 39.2%  and  44.5%  of the patient  subgroups,  as  opposed  to  74.5%  (NICE),  68.7%  (SMC),
and  68.9%  (PBAC),  respectively.
Conclusion:  We  show  that the  FJC – an agency  relatively  new  in  structurally  assessing  the
health  beneﬁt  of  pharmaceuticals  – deviates  considerably  in  decisions  compared  to  other
HTA  agencies.  Our study  also  reveals  that the  FJC  tends  to  appraise  stricter  than  NICE.
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1. Introduction
Fourth-hurdle decision making helps to decide on a
new pharmaceutical’s coverage and reimbursement within
a health care system. It is called ‘fourth-hurdle’ because
the pharmaceutical has already passed three hurdles to
achieve market authorization thereby demonstrating its
safety, efﬁcacy and quality [1,2]. Given the need to allocate
 access article under the CC BY-NC-ND license (http://creativecommons.
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scarce resources and to contain pharmaceutical expen-
diture, many countries have established fourth-hurdle
decision making to assess and appraise technologies over
the last two decades [3]. Among them are Australia,
Belgium, Canada, England and Wales, Scotland, Sweden
and the Netherlands [4]. The general aim is to assess the
trade-off between health beneﬁt and a pharmaceutical’s
cost. Despite being Europe’s largest pharmaceutical mar-
ket in terms of sales volume, Germany was a late-mover
to implement the fourth hurdle in January 2011, by the
Pharmaceutical Market Restructuring Act (AMNOG).
Within three months after market launch, all newly
introduced pharmaceuticals are evaluated based on their
added beneﬁt over a comparator, the so-called Early Bene-
ﬁt Assessment (EBA) [5]. By law, manufacturers are obliged
to submit a dossier to the Federal Joint Committee (FJC).
Within six months after submission, the FJC performs the
appraisal. Whilst the ﬁnal decision is with the FJC, the
Institute for Quality and Efﬁciency in Health Care (IQWiG)
is, by convention, commissioned for a preliminary assess-
ment. While IQWiG assesses the evidence submitted by
the manufacturer in the ﬁrst place, FJC is responsible for
the ﬁnal decision after a separate assessment of the evi-
dence. It has been shown that FJC tends to soften IQWiG’s
decisions [6]. If an added beneﬁt is approved by FJC, in a
separate stage, the manufacturer and the Federal Associ-
ation of Sickness Funds negotiate a price within another
six months. Pharmaceuticals that do not show an added
beneﬁt become subject to reference pricing or other reim-
bursement restrictions.
To date, evidence on the German system focusses on
discussions on the beneﬁts and limitations of the AMNOG
reform itself, the outcomes of the ﬁrst wave of EBAs
and the agreement between manufacturers, IQWiG and
FJC [6–13]. However, little is known about how the FJC’s
judgements compare to other health technology assess-
ment (HTA) agencies. First international comparisons have
revealed differences in the process and provided qualita-
tive overviews of decisions by therapeutic areas and prices
[14,15]. Other studies examine consideration of indirect
comparisons [10] or quality of life [16] in appraisals. This
is of relevance to both the pharmaceutical industry and
health policy makers.
While pharmaceutical product development aims to
cover multiple health care markets, regulation ideally fol-
lows country speciﬁc preferences. This is why there are
varying preferences towards the process and methods
of evaluating new pharmaceuticals [17]. For this reason,
the institutions that have emerged share some common
features, but also differ in others. For the ﬁnal decision,
important criteria in many systems are the appraisal of
comparative effectiveness, i.e. the appraisal of ‘clinical
information on the relative merits or outcomes of one inter-
vention in comparison to one or more others’  [18] and,
cost-effectiveness that analyses a substance’s beneﬁts in
face of its cost. While cost-effectiveness is not consid-
ered in the FJC process, it is a common criterion of nearly
all HTA agencies in the appraisal process. Comparative
research thus helps (a) pointing out areas of disagree-
ment between agencies when performing the same or
similar tasks, (b) identifying and explaining drivers for 120 (2016) 1115–1122
deviation in outcomes and (c) improving decision-making
processes.
Previous research has analysed the fourth hur-
dle through various means [19,20]. First quantitative
approaches have focussed on the ﬁnal appraisal, i.e. the
resulting decision that may  rest on varying criteria across
HTA agencies and the appraisal of comparative effec-
tiveness [21,22]. Qualitative approaches have explored
possible reasons for variations in decisions by variation in
the decision-making criteria and the reasons for differences
in HTA including the varying interpretation in underlying
uncertainty of the evidence [23]. Such approaches typically
cover a smaller sample of decisions and speciﬁc product
categories that allows in-depth analysis of the interpreta-
tion of available evidence by all types of sub-criteria and
including the full complexity of decision-making. In this
study, we focus on the ﬁnal decision and the assessment
of comparative effectiveness as these outcomes determine
the degree of implementation in the health system after the
decision and constitute what is perceived by stakeholders
ﬁrst.
The objective of this study was  thus to compare the
decisions of the German FJC with three other HTA agen-
cies. We  chose the English National Institute for Health and
Care Excellence (NICE), the Scottish Medicines Consortium
(SMC), and the Australian Pharmaceutical Beneﬁts Advi-
sory Committee (PBAC) as comparator HTA agencies. As a
ﬁrst step, we analysed the decisions made jointly by the FJC
and the other agencies between 2011 and 2014. Finally, we
partially explored drivers for deviances in outcome.
2. Comparator agencies
Evaluations of beneﬁt in all four agencies are conducted
in two  stages, as separate institutions for assessment and
appraisal are involved. FJC, NICE and PBAC appraisals
are comprehensive, while SMC  conducts a ‘rapid early
review’ [24]. The trigger for the beneﬁt assessment process
differs: FJC and SMC  appraise all newly licensed pharma-
ceuticals, PBAC requires manufacturers to actively seek
reimbursement. NICE reviews all cancer drugs and most
new indications or new entities as it sees ﬁt. However, there
is no formal requirement to review new drugs/indications
to receive market access. This also implies differences in
the timing of the assessment. FJC, PBAC and SMC  appraise
new entities early in a drug’s post-development life cycle,
while the time frame for NICE appraisals may  vary. Fur-
thermore, the consequences for pharmaceuticals’ pricing
and reimbursement differ. A negative decision by NICE,
SMC  and PBAC will exclude a drug from reimbursement.
This may  base on unfavourable comparative effective-
ness or, if health beneﬁts are present, cost-effectiveness.
A negative decision of the FJC that solely rests on con-
siderations of comparative effectiveness will ‘only’ impact
reimbursement prices. Thus, the results from the appraisal
of comparative effectiveness have differing consequences.
With respect to the type of evidence taken into account
in the decision-making process, all agencies use clinical
evidence for their appraisals. While the FJC’s assessment
is totally limited to clinical evidence and only evaluates
comparative effectiveness [6], NICE, SMC  and PBAC follow
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Table  1
Differences and similarities of assessment processes in Germany, England Scotland and Australia.
HTAa Agency FJCb NICEc SMCd PBACe
Characteristic
Consideration of comparative effectiveness in ﬁnal decision Yes Yes Yes Yes
Consideration of cost effectiveness in ﬁnal decision No Yes Yes Yes
2-stage-process (assessment/appraisal) Yes Yes Yes Yes
Appraisal selection criteria All newly licensed
pharmaceuticals
and new
indications
If mandated by the
Department of
Health
All newly licensed
pharmaceuticals
and new
indications
Manufacturer
submission
Approx. process duration 6 months 9–12 months 3 months 4–5 months
a HTA = health technology assessment.
b FJC = Federal Joint Committee.
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tc NICE = National Institute for Health and Care Excellence.
d SMC  = Scottish Medicines Consortium.
e PBAC = Pharmaceuticals Beneﬁts Advisory Committee.
 ‘value-for-money’ approach in addition and their assess-
ent includes cost-effectiveness [25–27]. Given that the
nal decision may  vary across HTA agencies because of
he diverging criteria between FJC (i.e. comparative effec-
iveness) and NICE, SMC, and PBAC (i.e. cost-effectiveness,
ost minimization), besides the ﬁnal decision, we compare
he appraisals of comparative effectiveness in this study.
echnologies which are not considered effective in terms
f health beneﬁt are typically dominated in terms of cost-
ffectiveness. Besides, cost-effectiveness considerations
re subject to strategic pricing behaviour of manufactur-
rs. Table 1 provides an overview of the key differences and
imilarities of the four HTA agencies that were included
n our analysis. Details have been described elsewhere
24,28–30].
. Methods
.1. Study setting
To begin with, we screened all EBAs of the FJC con-
luded between January 2011 and December 2014 and
xtracted data on decisions on the patient-subgroup level.
n case of revisions, we only considered the latest decision.
ecisions that were ongoing, had no status, were discon-
inued or involved pharmaceuticals that were suspended
rom AMNOG were excluded. Subsequently, we  extracted
ll data on decisions of NICE, SMC  and PBAC appraisals for
hich a corresponding FJC-decision on patient subgroup-
evel existed.
For FJC decisions and information on the corresponding
BAs, we used a database developed by the Ham-
urg Center for Health Economics (HCHE). The database
uilds on publicly available data from the FJC’s website
www.g-ba.de) and has been used in previous research [6].
or NICE, SMC  and PBAC decisions and underlying bene-
t assessments, data were extracted from public summary
ocuments available from the agencies’ websites (NICE:
ww.nice.org.uk; SMC: www.scottishmedicines.org.uk;
BAC: www.pbs.gov.au).Data extraction was performed in several consecutive
teps. In a ﬁrst step, we captured the overlap of deci-
ions between FJC and the other HTA agencies. To ensure
hat decisions and extracted data are comparable in theirscope, we deﬁned a set of variables that capture the sub-
stance, main indication, patient subgroup and whether an
appraisal was  performed at subgroup level by the respec-
tive agency. This process was pre-tested with a small set of
decisions and then performed consistently across the three
other HTA agencies. In a second step we  matched deci-
sions of the other HTA agencies if they covered the patient
subgroup considered or a wider group of patients as the
patient subgroups of FJC are often more reﬁned. Finally,
we extracted the ﬁnal decision and comparative effective-
ness considerations through two separate reviewers. All
conﬂicts were resolved by discussion between the three
authors.
To ensure that the scope of the decisions was  simi-
lar across HTA agencies, we  captured the pharmaceutical’s
main indication. As HTA agencies frequently specify a num-
ber of patient subgroups by clinical criteria, we  also ensured
that these were equal between the FJC and the other three
agencies.
3.2. Outcome measurement
The ﬁnal decision of the four HTA agencies was our
outcome variable to analyse agreement. To ensure com-
parability with the other HTA agencies, we  used binary
coding (‘added beneﬁt’, ‘no added beneﬁt’) for the FJC deci-
sions. The FJC categories ‘major’, ‘considerable’, ‘minor’, or
‘non-quantiﬁable added beneﬁt’ were considered for the
category ‘added beneﬁt’. The other two  categories, ‘no evi-
dence of added beneﬁt’ and ‘less beneﬁt’, were combined
to ‘no added beneﬁt’.
As the FJC decides on comparative effectiveness only,
we collected data on NICE, PBAC and SMC  judgement’s
in two ways: (a) We  collected data on the ﬁnal decision
of the other HTA agencies, i.e. cost-effectiveness. Again,
we differentiated between positive ratings (i.e. recom-
mended/recommended with restriction for NICE and PBAC
and accepted/accepted with restriction for SMC) and neg-
ative ratings (i.e. not recommended for NICE, SMC  and
rejected for PBAC). (b) On a separate basis, we collected data
on the HTA agencies’ rating on a pharmaceutical’s compar-
ative effectiveness only. We  differentiated between ‘better’
if the HTA agency stated that the pharmaceutical is supe-
rior in comparative effectiveness or ‘similar or not proven’.
h Policy1118 K.E. Fischer et al. / Healt
We  consider this categorization to be equivalent to the FJC’s
ﬁnal decision (added beneﬁt/no added beneﬁt). Due to the
extraction of judgements being prone to subjectivity, the
rating of comparative effectiveness was extracted by two
independent reviewers. Any disagreement was  resolved
by discussion. Interrater reliability was substantial, with
a Cohen’s Kappa of 0.78 for NICE, 0.85 for SMC  and 0.82 for
PBAC ratings of comparative effectiveness.
To conclude in a rating of health beneﬁt, the FJC
appraises health outcomes in four categories of clinical
endpoints – mortality, morbidity (of a disease’s medical
conditions), adverse events and quality of life – in every
patient subgroup. We  captured the other HTA agencies’
ratings of clinical endpoints as for the FJC. Using this infor-
mation, we created dummy  variables to express agreement
between the FJC and the other HTA agencies in endpoints.
We deﬁned agreement as positive (FJC: added beneﬁt;
NICE/SMC/PBAC: better) or negative (FJC: no added ben-
eﬁt; NICE/SMC/PBAC: similar or not proven) rating in each
of the four endpoint categories. As these variables were
again prone to subjectivity, data were extracted indepen-
dently by two reviewers. Disagreement was resolved by
discussion. Across endpoints, interrater reliability varied.
Highest agreement was for mortality (mean kappa: 0.79)
and lowest was for morbidity (mean kappa: 0.30).
In addition, we captured (a) the difference in the number
of RCTs available to the FJC and each of the other HTA agen-
cies, (b) the number of months between the FJCs decision
and the decision of each of the other HTA agencies and (c)
whether the comparator(s) of each of the three HTA agen-
cies include(s) (potentially among others) the comparator
used by the FJC.3.3. Statistical analysis
We  performed descriptive analyses by contrasting the
FJC decisions on the level of patient subgroups in two  ways.
Fig. 1. Early Beneﬁt Assessments (EBAs) and correspo 120 (2016) 1115–1122
We  compared (a) the corresponding ﬁnal decision of FJC
and the other HTA agencies (i.e. e.g. added beneﬁt/no added
beneﬁt vs. recommended/not recommended) and (b) only
the corresponding judgements on comparative effective-
ness (i.e. added beneﬁt/no added beneﬁt vs. better/similar
or not proven). For each comparison, we analysed the
agreement between FJC and each of the other HTA agencies.
Agreement was  quantiﬁed by calculating Cohen’s Kappa, a
measure to determine whether agreement between two
raters is by chance [31]. Kappa ranges from −1 to 1; with
a value less than or close to 0 indicating that agreement
is due to chance. A value of 1 indicates perfect agreement
whilst the −1 reﬂects perfect disagreement. All analyses
were performed using R version 2.15.3.
4. Results
4.1. Description of study sample
118 EBAs had been concluded by FJC within the time-
frame of our study. Of these, we  excluded 19 according
to our exclusion criteria. For the remaining 99 EBAs that
included in total 192 patient subgroups, we identiﬁed cor-
responding appraisals for NICE (35), SMC  (66) and PBAC
(66), respectively. These represented 55 (NICE), 166 (SMC)
and 119 (PBAC) patient subgroups (see Fig. 1). For the com-
parison FJC-NICE, the majority of patient subgroups were
in the disease categories ‘neoplasms’ (44%), ‘diseases of
the nervous system’ (15%) and ‘diseases of the circula-
tory system’ (13%). For FJC-SMC and FJC-PBAC, top three
disease categories were ‘infectious and parasitic diseases’
(FJC-SMC: 20%, FJC-PBAC: 21%), ‘neoplasms’ (FJC-SMC: 24%,
FJC-PBAC: 26%) and ‘endocrine nutritional and metabolic
diseases’ (FJC-SMC: 28%, FJC-PBAC: 22%). Furthermore,
there were a number of patient subgroups in each com-
parison where orphan drugs have been indicated for: 4
patient subgroups in the comparison between NICE and
nding appraisals of FJC, NICE, SMC  and PBAC.
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JC, 20 in the FJC-SMC and 13 in the FJC-PBAC comparison,
espectively.
.2. Agreement in decisions
Agreement in ﬁnal decision (added beneﬁt/no added
eneﬁt vs. recommended/not recommended) between the
JC and the three other HTA agencies was low (Table 2):
JC and NICE agreed in only 40% (22 of 55 patient groups)
f their ratings. Results were similar for the comparisons
JC-SMC and FJC-PBAC, with 47.6% (79 of 166) and 48.7%
58 of 119) agreement, respectively. Coefﬁcients of Cohen’s
appa also indicated low agreement with −0.13, 0.03 and
.07 for the comparison of FJC with NICE, SMC  and PBAC,
espectively.
Agreement improved moderately when comparing FJC
ecisions with the other agencies’ judgements on compara-
ive effectiveness only: FJC agreed with NICE in 52.7%, with
MC  in 64.5%, and with PBAC in 69.7% of patient subgroups.
gain, estimates of Cohen’s Kappa indicate low agreement,
ith 0.11, 0.26 and 0.38, respectively. Across all compar-
sons of agreements, the results reveal a consistent pattern.
The FJC rated substantially fewer patient subgroups pos-
tive in its ﬁnal decision than the other three HTA agencies.
he FJC decided positive only in 43.6%, 39.2% and 44.5% of
he patient subgroups, as opposed to 74.5% (NICE), 68.7%
SMC), and 68.9% (PBAC), respectively.
.3. Agreement in endpoints and choice of comparatorTo compare agreement in endpoints, we excluded those
ppraisal decisions where manufacturers did not submit a
ossier (FJC: 19 patient subgroups; NICE: 3; SMC: 26; PBAC:
able 2
ICE, SMC  and PBAC decisions and comparative effectiveness estimates by FJC de120 (2016) 1115–1122 1119
2) or data on some of our variables was  not reported in
public summary documents (12 patient subgroups for FJC-
SMC, 4 patient subgroups for FJC-PBAC). Thus, our results
were based on 48 (FJC-NICE), 122 (FJC-SMC) and 109 (FJC-
PBAC) patient subgroups.
Agreement in endpoints between the agencies was
highest for adverse events (92% for FJC-NICE, 77% for FJC-
SMC  and 77% for FJC-PBAC) and quality of life (85% for
FJC-NICE, 89% for FJC-SMC and 96% for FJC-PBAC) followed
by mortality (71% for FJC-NICE, 83% for FJC-SMC and 83%
for FJC-PBAC). However, one has to keep in mind that these
were also the categories where ‘no additional beneﬁt’ or
‘similar/not proven’ was scored more often, thus leading
to agreement in a negative decision. For morbidity, FJC and
the other agencies agreed least often (52% for FJC-NICE, 60%
for FJC-SMC and 64% for FJC-PBAC).
The comparator(s) used by the FJC was  also allowed by
the three other HTA agencies (potentially among others) in
71% of decisions for NICE, 56% for SMC  and 50% for PBAC,
respectively.
5. Discussion
This study contributes to the research on coverage and
reimbursement decision-making by examining whether
and to what extent decisions of the FJC deviated from
those of other HTA agencies. Our ﬁndings further support
developing hypotheses on what may  drive FJC decisions as
opposed to other HTA agencies. This also allows initiating
a discussion whether the outcomes of FJC’s appraisal pro-
cess are in accordance with the preferences of the German
population. In particular, as decisions are put in a broader,
international context.
cision.
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We  identiﬁed substantial disagreement in ﬁnal deci-
sions between the FJC and the other HTA agencies. This
ﬁnding is not completely unexpected, given the differences
in the HTA agencies’ mandates, characteristics and their
decision-making processes. Reviewing the existing litera-
ture to similar international comparisons, several authors
compared methodological aspects of health beneﬁt assess-
ment procedures [4,32–34]. Generally, our ﬁndings are in
line with other studies, which also showed that HTA agen-
cies disagree in their decisions [29,35–38]. For example,
Nicod and Kanavos report poor to moderate agreement in
comparing NICE, PBAC, SMC, the Canadian Common Drug
Review and the Swedish Dental and Pharmaceutical Bene-
ﬁts Board [37]. Still, it is surprising that the disagreement
persists when the comparison between the HTA agencies
is limited to the judgement of comparative effectiveness
only.
As orphan drugs are frequently considered in special
in decision processes [39,40], we accounted for potential
differences by excluding decisions on orphan drugs across
HTA agencies as a sensitivity analysis. Results remained
robust. The coefﬁcients of Cohen’s Kappa for the agree-
ment in ﬁnal decision (FJC-NICE: −0.06; FJC-SMC: 0.07;
FJC-PBAC: 0.006) and comparative effectiveness (FJC-NICE:
0.11; FJC-SMC: 0.26; FJC-PBAC: 0.40) were similar to the full
sample.
The extent of disagreement may, however, also raise
concerns given the overlap in the evidence that was sub-
mitted to all agencies. The absolute difference in the
number of RCTs between FJC and the other HTA agencies
was, on average, one study (1.02 studies for FJC vs. NICE,
1.23 for FJC vs. SMC  and 1.05 for FJC vs. PBAC). However,
when contrasting the ﬁnal decisions between NICE, SMC
and PBAC based on our sample, a high level of agreement
was only found between NICE and SMC  (70% agreement
based on 50 subgroups, Cohen’s Kappa: 0.63). The level
of agreement between NICE and PBAC (61% based on 41
patient subgroups, Cohen’s Kappa: 0.23) and between SMC
and PBAC (50% based on 111 patient subgroups, Cohen’s
Kappa: 0.11) was similar to the comparisons to the FJC. This
suggests that agreement between HTA agencies is rather
the exception than the rule.
Part of the differences in decision-making may  be
related to the impact of an agencies’ decision on patient
access. Whereas a negative decision by NICE, SMC  as well
as PBAC excludes a drug from reimbursement and thus
automatically restricts patient access, the consequences
of FJC decisions are not that severe. In fact, when the FJC
does not ﬁnd an ‘added beneﬁt’, the drug will still be reim-
bursed although at a (potentially) much lower price. This
means that the drug will be subject to other regulations
such as reference pricing. However, unless the manufac-
turer withdraws its pharmaceutical from the market, FJC’s
decisions do not compromise patient access (just manu-
facturer’s proﬁts). This could explain the more strict line
in decision-making of the FJC compared to the three other
HTA agencies.We  also identiﬁed explanations that are rooted in devia-
tions of the methodological framework of the agencies: (1)
Agencies differ in accepting endpoints such as recognising
the surrogate endpoint progression-free-survival. Another 120 (2016) 1115–1122
example is to prefer disease-speciﬁc mortality over over-
all mortality as endpoint or vice versa. (2) Agencies differ
in the choice of comparator(s). For example, when decid-
ing on the added beneﬁt for Apixaban for the treatment of
atrial ﬁbrillation, the FJC viewed Vitamine-K-Antagonists
as comparators whereas NICE and SMC  deﬁned Rivaroxa-
ban and Dabigatran in addition to Vitamine-K-Antagonists
as comparators. PBAC even went further by adding
acetylsalicylic acid to the list of comparators. This will
render the same evidence useful for the appraisal of one
agencies whereas it cannot be used in the appraisal of
another agency. (3) There are differences in handling lack
of evidence. An example may  arise from the decisions made
on Apixaban for the treatment of pulmonary embolism
and for the prevention of recurrent venous thromboem-
bolism. Whereas NICE and FJC both agree that evidence was
only presented for short term prophylaxis, NICE concluded
that there was  no evidence of a difference in the effective-
ness to the two other agents in that class (rivaroxaban and
dabigatran) [41]. For rivaroxaban it had judged earlier on
the absence of evidence: ‘the committee accepted that there
was no [. . .]  reason why the effects [. . .]  would not be main-
tained over the longer term’ [42], whereas FJC concluded
that the manufacturer had not provided data and thus no
added beneﬁt was  found. (4) Strategic behaviour may  strain
outcomes of initial submissions. As manufacturers submit
a price suggestion in Australia upon submission, PBAC is
likely to have taken a tougher line on aspects of evidence
in part to reduce prices on resubmission. (5) The systems
included are at different maturity stages in the implemen-
tation of the fourth hurdle. Having started appraisal of
health beneﬁt not until 2011, FJC has about 10 years less
experience in evaluating pharmaceuticals on a regular basis
compared to NICE.
Other authors named agency processes, attitudes to
the added beneﬁt of a new pharmaceutical within an
established therapeutic class including clinical and eco-
nomic evidence, differences in the extent of required
information, date of decision, the rigour of the appraisal,
characteristics of the reimbursement system and the coun-
try’s socioeconomic situation as reasons for differences in
decision-making [29,35,36].
Our study has several methodological limitations. Most
importantly, our analyses only cover components and deci-
sions that are present across at least two decision-making
processes. For the time frame of our study, we  included
about 32%/39%/20% of NICE’s/SMC’s/PBAC’s total number
of technology appraisals. Restricting the decisions to those
where a paired comparison is possible may  not show the
other HTA agencies’ typical decision-making behaviour.
However, compared to similar studies published in the lit-
erature, our results appear to be valid. For example, for the
patient subgroups included in our study, the proportion of
positive ﬁnal decisions of FJC, NICE, SMC, and PBAC was
39–45%, 75%, 69% and 69%, respectively. Those found by
other authors ranged from 39 to 50% for FJC [6,13], 71 to
87% for NICE [22,29,35,43,44], 57 to 68% for SMC  [3,29,45],
and 62 to 74% for PBAC [29,35]. Of course, our results could
also be inﬂuenced by the process of data extraction.
Although we  carefully chose to compare patient sub-
groups between FJC and the other HTA agencies, these do
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ot always represent perfect matches. In some appraisals,
ICE, SMC  or PBAC appraised the substance in the same
ndication, but not all patient subgroups were deﬁned
xactly the same as by the FJC. For example, for Sofos-
uvir in the treatment of chronic hepatitis C infection,
he FJC deﬁned patient subgroups according to treatment
xperience and genotype. One patient subgroup speciﬁ-
ally corresponded to patients with HIV-coinfection. The
BAC, however, likewise referred to treatment experience
nd genotype, but did not comment on HIV-coinfections
eparately. Moreover, the exact endpoints considered and
omparator against which a substance is appraised may  dif-
er across HTA agencies. Thus, decisions may  differ not by
iverging views on comparative effectiveness, but based on
arying reference points, i.e. deﬁnitions of comparators and
ndpoints. However, the selection of comparators typically
s not exogenous in the appraisal process.
Another aspect that inﬂuences the degree of implemen-
ation of a product is the extent of uncertainty underlying
he decision. For this purpose, FJC provides an explicit cat-
gorical rating to display the degree of uncertainty of the
vidence considered. A very detailed analysis of reasons
or deviances in outcomes has been conducted by Nicod
nd Kanavos based on two assessments in England, Scot-
and, Sweden and France [23]. The study shows that NICE
ejected one of the substances because of uncertainty in
ost-effectiveness.
. Conclusions
In modern health care systems, fourth hurdle decision-
aking plays a key role in assuring sustainable use of
esources to guarantee that patients will receive adequate
nd likewise effective treatments in the long run. The
resent study showed that the German FJC, that is rel-
tively new to the ﬁeld of health beneﬁt assessment of
harmaceuticals, considerably deviates in its outcomes
rom established HTA agencies, even when only consider-
ng aspects of comparative effectiveness. While this can be
ttributed to differences in the agencies’ mandates, charac-
eristics as well as the consequences of a negative decision
or patient access, our study reveals that the FJC tends to
ppraise stricter in terms of comparative effectiveness than
ICE.
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